Stocks TradingCharts.com

stocks prices, charts & quotes

Free Stock Prices, Charts & Stock Price Quotes

Search
Symbol Search Browse Symbols My Charts Menu
QUICK QUOTE
QUICK CHART
F.A.Questions Suggestion Box Advertising Info Commodity Charts Forex Markets

Stocks & Financial News

Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts

Establishment Labs Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference

SANTA BARBARA, Calif., January 13, 2021 (BUSINESS WIRE) --
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan Jose Chacon-Quiros will participate in the 39th Annual J.P. Morgan Healthcare Conference, which is being held January 11-14, 2021. Mr. Chacon-Quiros is scheduled to speak to conference attendees at 4:30 pm ET on Thursday, January 14, 2021.

A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants(R), the centerpiece of the MotivaImagine(R) platform. Motiva Implants(R) are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company's direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant(R) clinical trial in the United States in April 2018. In addition to Motiva Implants(R), Establishment Labs' product and technologies portfolio includes the Divina(R) 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005229/en/

SOURCE: Establishment Labs Holdings Inc.

<img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20210113005229r1&sid=cmtx6&distro=nx&lang=en" style="width:0;height:0" />

Investor/Media Contact: 
David K. Erickson
949-447-6671
derickson@establishmentlabs.com
comtex tracking

Do not sell my personal information

Copyright © 2021. All market data is provided by Barchart Solutions. Information is provided "as is" and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.